Hester Biosciences [HESTERBIO] vs Themis Medicare [THEMISMED] Detailed Stock Comparison
Hester Biosciences
NSE
Loading...
Themis Medicare
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Hester Biosciences wins in 11 metrics, Themis Medicare wins in 8 metrics, with 0 ties. Hester Biosciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Hester Biosciences | Themis Medicare | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 48.54 | 32.38 | Themis Medicare |
| Price-to-Book Ratio | 5.76 | 2.29 | Themis Medicare |
| Debt-to-Equity Ratio | 68.46 | 20.61 | Themis Medicare |
| PEG Ratio | 0.37 | -0.21 | Themis Medicare |
| EV/EBITDA | 29.94 | 108.54 | Hester Biosciences |
| Profit Margin (TTM) | 11.92% | -2.39% | Hester Biosciences |
| Operating Margin (TTM) | 24.24% | -12.95% | Hester Biosciences |
| EBITDA Margin (TTM) | 24.24% | N/A | N/A |
| Return on Equity | 8.41% | 7.41% | Hester Biosciences |
| Return on Assets (TTM) | 4.21% | 5.07% | Themis Medicare |
| Free Cash Flow (TTM) | $439.20M | $192.84M | Hester Biosciences |
| Dividend Yield | 0.64% | 0.50% | Hester Biosciences |
| 1-Year Return | -11.94% | -62.93% | Hester Biosciences |
| Price-to-Sales Ratio (TTM) | 5.74 | 2.44 | Themis Medicare |
| Enterprise Value | $20.40B | $9.96B | Hester Biosciences |
| EV/Revenue Ratio | 6.47 | 2.62 | Themis Medicare |
| Gross Profit Margin (TTM) | 73.29% | 46.30% | Hester Biosciences |
| Revenue per Share (TTM) | $361 | $41 | Hester Biosciences |
| Earnings per Share (Diluted) | $43.86 | $-0.98 | Hester Biosciences |
| Beta (Stock Volatility) | 0.12 | -0.22 | Themis Medicare |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Hester Biosciences vs Themis Medicare Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Hester Biosciences | -0.89% | 2.87% | 9.56% | 14.21% | 54.66% | -11.43% |
| Themis Medicare | -1.42% | -3.14% | -6.50% | -30.62% | -35.59% | -61.91% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Hester Biosciences | -11.94% | 1.52% | 20.80% | 260.00% | 358.43% | 358.43% |
| Themis Medicare | -62.93% | -89.92% | -70.45% | -51.75% | -58.49% | -22.87% |
News Based Sentiment: Hester Biosciences vs Themis Medicare
Hester Biosciences
News based Sentiment: MIXED
Hester Biosciences reported strong profit growth in the June quarter, but this was offset by concerns about high debt levels and a stock that has underperformed over the past year. The fundamental analysis report highlighting overvaluation adds to the complexity of the investment picture, making September a month of mixed signals.
Themis Medicare
News based Sentiment: NEGATIVE
Themis Medicare is experiencing significant financial difficulties, with consecutive quarterly losses and a substantial decline in its stock price. While the annual profit offers a slight offset, the overall trend is concerning for investors, making this a key month for monitoring the company's performance and future prospects.
Performance & Financial Health Analysis: Hester Biosciences vs Themis Medicare
| Metric | HESTERBIO | THEMISMED |
|---|---|---|
| Market Information | ||
| Market Cap | ₹18.15B | ₹9.27B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 6,827 | 44,515 |
| 90 Day Avg. Volume | 22,113 | 275,340 |
| Last Close | ₹2,117.70 | ₹100.50 |
| 52 Week Range | ₹1,242.95 - ₹2,786.10 | ₹98.00 - ₹317.00 |
| % from 52W High | -23.99% | -68.30% |
| All-Time High | ₹3,379.00 (Jul 22, 2024) | ₹1,834.00 (Sep 25, 2023) |
| % from All-Time High | -37.33% | -94.52% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.04% | -0.21% |
| Quarterly Earnings Growth | 1.60% | -0.21% |
| Financial Health | ||
| Profit Margin (TTM) | 0.12% | -0.02% |
| Operating Margin (TTM) | 0.24% | -0.13% |
| Return on Equity (TTM) | 0.08% | 0.07% |
| Debt to Equity (MRQ) | 68.46 | 20.61 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹369.41 | ₹43.74 |
| Cash per Share (MRQ) | ₹8.49 | ₹1.39 |
| Operating Cash Flow (TTM) | ₹554.94M | ₹382.22M |
| Levered Free Cash Flow (TTM) | ₹274.88M | ₹298.33M |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.64% | 0.50% |
| Last 12-Month Dividend | ₹13.00 | ₹0.50 |
Valuation & Enterprise Metrics Analysis: Hester Biosciences vs Themis Medicare
| Metric | HESTERBIO | THEMISMED |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 48.54 | 32.38 |
| Forward P/E | N/A | N/A |
| PEG Ratio | 0.37 | -0.21 |
| Price to Sales (TTM) | 5.74 | 2.44 |
| Price to Book (MRQ) | 5.76 | 2.29 |
| Market Capitalization | ||
| Market Capitalization | ₹18.15B | ₹9.27B |
| Enterprise Value | ₹20.40B | ₹9.96B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.47 | 2.62 |
| Enterprise to EBITDA | 29.94 | 108.54 |
| Risk & Other Metrics | ||
| Beta | 0.12 | -0.22 |
| Book Value per Share (MRQ) | ₹369.41 | ₹43.74 |
Financial Statements Comparison: Hester Biosciences vs Themis Medicare
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | HESTERBIO | THEMISMED |
|---|---|---|
| Revenue/Sales | ₹841.05M | ₹717.02M |
| Cost of Goods Sold | ₹224.62M | ₹205.88M |
| Gross Profit | ₹616.43M | ₹511.13M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹186.32M | ₹-83.16M |
| EBITDA | ₹261.79M | ₹-61.45M |
| Pre-Tax Income | ₹201.87M | ₹-111.27M |
| Income Tax | ₹28.91M | ₹-14.62M |
| Net Income (Profit) | ₹172.96M | ₹-96.65M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | HESTERBIO | THEMISMED |
|---|---|---|
| Cash & Equivalents | ₹55.87M | ₹65.59M |
| Total Current Assets | ₹1.95B | ₹3.04B |
| Total Current Liabilities | ₹1.25B | ₹1.56B |
| Long-Term Debt | ₹1.39B | ₹186.12M |
| Total Shareholders Equity | ₹3.27B | ₹4.03B |
| Retained Earnings | ₹2.37B | N/A |
| Property, Plant & Equipment | ₹59.22M | ₹1.72B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | HESTERBIO | THEMISMED |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | HESTERBIO | THEMISMED |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 6,827 | 44,515 |
| Average Daily Volume (90 Day) | 22,113 | 275,340 |
| Shares Outstanding | 8.51M | 92.04M |
| Float Shares | 2.68M | 21.72M |
| % Held by Insiders | 0.69% | 0.76% |
| % Held by Institutions | 0.00% | 0.00% |
Dividend Analysis & Yield Comparison: Hester Biosciences vs Themis Medicare
| Metric | HESTERBIO | THEMISMED |
|---|---|---|
| Last 12-Month Dividend | ₹13.00 | ₹0.50 |
| Last 12-Month Dividend Yield | 0.64% | 0.50% |
| 3-Year Avg Annual Dividend | ₹10.33 | ₹0.37 |
| 3-Year Avg Dividend Yield | 0.37% | 0.18% |
| 3-Year Total Dividends | ₹31.00 | ₹1.10 |
| Ex-Dividend Date | Aug 06, 2025 | Sep 04, 2025 |